Despite excitement over the potential of radiopharmaceuticals as cancer treatments, drug developers are hitting new hurdles.

Despite excitement over the potential of radiopharmaceuticals as cancer treatments, drug developers are hitting new hurdles.

The FDA has rejected a radiopharmaceutical therapy due to manufacturing issues, halting what would have been a competitor for Novartis.